Biogen Inc Earnings
The next earnings date for Biogen Inc is July 29, 2026.
They are scheduled to announce earnings before the market opens that day.
Analyst Estimates of Biogen Inc Earnings
| 07/29/2026 | $3.35 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
Biogen Inc Earnings: Historical
| 04/29/2026 | Before Market | $3.57 | 23.53% |
| 02/06/2026 | Before Market | $1.99 | 22.84% |
| 10/30/2025 | Before Market | $4.81 | 23.97% |
| 07/31/2025 | Before Market | $5.47 | 40.98% |
| 05/01/2025 | Before Market | $3.02 | 2.37% |
| 02/12/2025 | Before Market | $3.44 | 2.38% |
| 10/30/2024 | Before Market | $4.08 | 7.65% |
| 08/01/2024 | Before Market | $5.28 | 31.02% |
| 04/24/2024 | Before Market | $3.67 | 6.07% |
| 02/13/2024 | Before Market | $3.30 | 3.77% |
More About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
“Biogen Inc Earnings” Can Refer to the Biogen Inc Earnings Date
Some people say “Biogen Inc earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my Biogen Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning Biogen Inc Stock on the Earnings Date
If you own Biogen Inc stock (BIIB) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Biogen Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading Biogen Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning Biogen Inc Options on the Earnings Date
If you own Biogen Inc options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of Biogen Inc options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own Biogen Inc options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for Biogen Inc. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of Biogen Inc options often go down. This is sometimes referred to as volatility crush.
Learning More Biogen Inc Earnings
You can contact us any time if you would like to ask questions about Biogen Inc earnings or anything else related to the stock market.